Chordia Therapeutics

Basic Information

Stock Code: 190A
Industry: Pharmaceuticals
Category Detail: Biotechnology & Pharmaceuticals
Prefecture: Kanagawa Prefecture
Establishment Year: October 2017
Listing Year: June 2024
Official Website: https://www.chordiatherapeutics.com/
TSE Information: TSE Information
Yahoo! Finance: Yahoo! Finance
Other Companies: GNI Group, Heartseed, Hmcomm, Nexera Pharma, CANBAS, Peptidream, SanBio, Helios, Brightpass, Rena Science, QualiPs, Takara Bio, Japan Tissue Engineering

Overview

Chordia Therapeutics is a bio-drug discovery company founded in 2017, an emerging enterprise that leverages cutting-edge gene-related technologies to focus on developing treatments centered on neurological diseases.

Current Situation

Since its founding, Chordia Therapeutics has dedicated itself to research and development of gene editing and novel therapies, listing on the Tokyo Stock Exchange in June 2024. Its main business is the development of cutting-edge pharmaceuticals in the bio-drug discovery field, enhancing competitiveness through innovative technologies. Based in Kanagawa Prefecture, it has partnered with U.S. venture capital firms to strengthen research funding. Currently conducting multiple clinical trials, it is garnering high expectations from the medical community. Aiming for sustainable healthcare provision, it is also exploring low-environmental-impact manufacturing processes. Moving forward, it plans to accelerate market expansion at home and abroad along with technological innovation, targeting the launch of multiple drugs by 2030. Capital increase through IPO has strengthened its financial base, aiming to become a leader in next-generation treatment fields.

Trivia

Interesting Facts

Growth company that achieved TSE Growth listing in 7 years since founding
One of the few domestic bio ventures with close capital ties to U.S. VCs
Possesses cutting-edge R&D facilities in Kanagawa Prefecture
Holds numerous patents related to CRISPR technology
Pioneer in early adoption of state-of-the-art AI drug discovery technology
Highly evaluated for promoting digitalization of clinical trials
Deploys numerous specialized brands focused on bio drug discovery
Focuses on environmentally considerate bio-pharmaceutical development
Founder is former university professor with strong scientific foundation
Multiple joint research projects underway with medical institutions
Noteworthy stock aiming for domestic and international drug approvals
History of excellence awards in Japan Bio Business Contest
Management policy considering contributions to regional revitalization
Regular participant in domestic bio-related events
Promotes innovative work styles internally

Hidden Connections

Secured abundant R&D funds through capital alliance with major U.S. VCs
Concluded multiple joint research contracts with university hospitals in Kanagawa Prefecture
Collaborating with adjacent IT company to develop AI drug discovery technology
Possibility of some technology exchange with main competitor Peptidream
Increasing presence as a key player in bio-related industry associations
Collaborating with environmental groups to reduce environmental impact in manufacturing processes
Major pharmaceutical company added as lead shareholder through recent third-party allotment capital increase
Closely cooperating with domestic clinical trial CROs to promote trial efficiency

Future Outlook

Growth Drivers

Market growth due to expanding demand for gene therapy
Increasing medical needs for neurological disease treatments
Strengthening domestic and international R&D partnerships
Acceleration of approvals for new therapeutic drugs
Development efficiency improvement through AI and digital technology introduction
Increased focus on sustainable manufacturing technologies
Aggressive expansion into global markets
Regulatory easing and changes in healthcare reimbursement systems
Expansion of pharmaceutical licensing business
Broadening technology applications to new business fields
Promotion of digitalization and efficiency in clinical trials
Potential for developing drugs responding to emerging infectious diseases

Strategic Goals

Commercialization of multiple gene therapies
Achieving annual sales exceeding 10 billion yen
Establishment of global clinical development network
Full realization of sustainable manufacturing systems
Establishment of AI-driven drug discovery processes
Stable funding through ongoing VC collaborations
Improved recognition and market share in major domestic and international markets
Innovation in clinical data analysis technology
Building diversity-focused talent development programs
Providing patient-centered treatment solutions

Business Segments

Gene Therapy Development Support

Overview

Provides services to support research and development of gene therapy and cell therapy.

Competitiveness

Advanced gene editing technology and clinical support system

Customers

Pharmaceutical Companies
Biotechnology Companies
Research Institutions
University Labs
Drug Development Companies
CROs (Contract Research Organizations)
Venture Capital Firms

Products

Gene Editing Technology Provision
Virus Vector Supply
Clinical Trial Support Services
Therapeutic Candidate Molecule Library
Drug Development Consulting

Pharmaceutical Technology Licensing

Overview

Provides licensing of advanced drug discovery technologies and platforms.

Competitiveness

Proprietary patent portfolio and extensive technology transfer track record

Customers

Major Pharmaceutical Companies
Bio Ventures
Medical Device Manufacturers
National Research Institutions
Overseas Licensing Partners

Products

Biomarker Technology
Advanced Therapy Platforms
Gene Vector Technology
Cell Culture Technology

Clinical Trial CRO Services

Overview

Provides comprehensive support for clinical trials of new drug candidates.

Competitiveness

Specialized medical staff and efficient project management

Customers

Pharmaceutical Companies
Bio Ventures
Medical Institutions
Clinical Trial Coordinators
Regulatory Authorities

Products

Clinical Trial Design
Subject Recruitment Support
Data Analysis
Regulatory Compliance Support

Cell Therapy Technology Provision

Overview

Supports and provides cell technology development for regenerative medicine.

Competitiveness

Cutting-edge stem cell technology and high-quality standards management

Customers

Regenerative Medicine Companies
University Hospitals
Drug Development Laboratories
Biomedical Companies

Products

Stem Cell Induction Technology
Cell Culture Technology
Cell Preservation Technology

Research-Use Bio Reagents Supply

Overview

Business providing high-quality reagents for life science research.

Competitiveness

High-precision reagent development and stable supply system

Customers

University Labs
Bio Startups
Pharmaceutical Development Teams
Public Research Institutions

Products

Gene-Related Reagents
Antibody Products
Cell Culture Reagents

Medical Data Analysis Services

Overview

Provides data analysis and AI support services for medical and drug discovery fields.

Competitiveness

Advanced data analysis technology and medical expertise

Customers

Pharmaceutical Companies
Medical Institutions
Research Institutions
IT Companies

Products

Bioinformatics Analysis
Clinical Data Management
AI Diagnostic Support Tools

Regulatory Compliance Consulting

Overview

Provides specialized support for regulatory compliance of pharmaceuticals, etc.

Competitiveness

Extensive regulatory knowledge and application track record

Customers

Pharmaceutical Manufacturers
Bio Ventures
Medical Device Manufacturers

Products

Approval Application Support
Quality Management System Development
Risk Management

Education and Talent Development Programs

Overview

Deploys training and education services related to drug discovery and medical technologies.

Competitiveness

Guidance by industry-leading experts

Customers

Medical Institutions
Pharmaceutical Companies
Universities

Products

Drug Discovery Technology Seminars
Clinical Trial Education
Gene Therapy Training

Bio Manufacturing Outsourcing

Overview

Provides pharmaceutical manufacturing outsourcing with advanced quality control.

Competitiveness

GMP-certified facilities and flexible production system

Customers

Pharmaceutical Manufacturers
Bio Companies
Contract Manufacturers

Products

Gene Therapy Formulation Manufacturing
Cell Therapy Formulation Manufacturing
GMP-Compliant Production

Medical Device Collaboration Business

Overview

Develops medical device technologies connecting drug discovery and clinical settings.

Competitiveness

Product development aligned with clinical needs

Customers

Medical Device Manufacturers
Hospitals
Research Institutions

Products

Drug Discovery Support Tools
Disease Monitoring Devices
Digital Health Technologies

Overseas Partnerships and Licensing Business

Overview

Supports market expansion through global joint development and technology provision.

Competitiveness

International network and negotiation capabilities

Customers

Overseas Pharmaceutical Companies
Biotech Companies
Research Consortia

Products

Technology Transfer Agreements
Joint Research
Overseas Market Expansion Support

Clinical Testing Outsourcing

Overview

Deploys clinical testing outsourcing services acting on behalf of clinical trials.

Competitiveness

Reliable SMO and CSO services

Customers

Pharmaceutical Companies
Research Institutions
CRO Companies

Products

Clinical Trial Management
Data Collection and Analysis
Quality Assurance

Competitive Advantage

Strengths

Possession of advanced gene editing technology
Diverse therapy development pipeline
Excellent clinical development infrastructure
Strategic partnerships with U.S. VCs
High number of technology patents
Aggressive research investments
Flexible product development response
Research bases consolidated in Kanagawa Prefecture
High-quality research team composition
Enhanced fundraising capabilities through listing
Accumulated clinical trial track record
Diversified business model
Domestic and international technology partnerships
Environmentally considerate development processes
Innovative bio-pharmaceutical development capabilities

Competitive Advantages

Precision medicine technology via gene editing
Treatment strategies specialized in neurological diseases
Securing funds and know-how through research collaborations with U.S. VCs
Simultaneous development system for diverse therapeutic candidates
Building domestic and international clinical trial networks
Possession of innovative bio-formulation manufacturing technology
High patent acquisition rate and intellectual property management
Close collaboration with medical institutions for clinical feedback
Improved credibility and fundraising power through listing
Development plans aimed at rapid market introduction
Business operations considering sustainability
Clinical trial management system utilizing digital technology
Aiming for early approval of new therapies
Flexibility to meet diverse market needs
Strong collaboration system with domestic bio companies

Threats

High hurdles and delay risks in drug approval
Intensified competition due to competitors' technological advances
Prolonged recovery period for R&D investments
Cost increases due to regulatory tightening
Uncertainty in global markets
Risks of bio technology patent disputes
Difficulty in securing clinical trial subjects
Impact of exchange rate fluctuations on fundraising
Risk of key talent outflow
Fluctuations in fundraising environment
Impacts from unstable international situations
Development failure risks due to technical barriers

Innovations

2024: Initiation of Phase II Clinical Trial for CT-101 Neuroregeneration Therapeutic Drug

Overview: Initiated Phase II clinical trial for novel therapeutic drug candidate promoting nerve cell regeneration.
Impact: Approval expectations rise with confirmation of clinical efficacy

2023: Proprietary Improvement of CRISPR Gene Editing Technology

Overview: Developed CRISPR technology with improved precision and safety.
Impact: Contributes to expansion of therapeutic applications

2022: Optimization of Drug Discovery Candidate Molecules Using AI

Overview: Achieved efficiency and success rate improvement in molecular design using artificial intelligence.
Impact: Contributes to shortened development periods and cost reductions

2021: Advancement of Stem Cell Induction Technology

Overview: Improved efficient and safe stem cell induction technology, with expectations for regenerative medicine applications.
Impact: Promotes commercialization in regenerative medicine field

2020: Development of Virus Vector Safety Enhancement Technology

Overview: Significantly improved safety and efficiency of therapeutic virus vectors.
Impact: Contributes to improved reliability of therapeutic drugs

2023: Introduction of Clinical Trial Management Platform

Overview: Adopted digital platform to improve clinical trial efficiency and data accuracy.
Impact: Achieves shortened trial periods and cost reductions

2022: Creation of Anti-Inflammatory Peptide Drug

Overview: Developed novel mechanism inflammation-suppressing peptide drug, currently in preclinical evaluation.
Impact: Expectations for applications in chronic disease treatment

2021: Development of Sustainable Manufacturing Processes

Overview: Established manufacturing methods adopting green chemistry to reduce environmental impact.
Impact: Improves company's sustainability evaluation

2024: Introduction of Clinical Data Analysis AI

Overview: Adopted AI technology for advanced clinical data analysis to enhance trial quality.
Impact: Contributes to improved reliability and acceleration of trials

2023: Initiation of Clinical Trial for Immune Modulation Therapeutic Drug

Overview: Initiated Phase I clinical trial for immune system modulator candidate for autoimmune diseases.
Impact: Expectations rise for new market development

Sustainability

Promotion of environmentally considerate manufacturing processes
Improvement of medical waste recycling
Development of energy-saving research facilities
Participation in local medical support volunteer activities
Adoption of sustainable resource procurement policies
Thorough employee health and safety management
Diversity and inclusion promotion in human resources policies
Contribution to improving medical access
Strengthening research on alternatives to animal testing
Promotion of green energy utilization
Regular publication of environmental reports
Paperless operations through digital processes